Article Text

Download PDFPDF

161 CUDU907 inhibits A549 proliferation by activating NDRG1
  1. Yuxia Huang and
  2. Wentian Zhang
  1. Shanghai Pulmonary Hospital, Shanghai, China
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.


Background At present, there are still great challenges in the treatment of tumors, and the role of NDRG1 in tumor proliferation has always been controversial.

Methods We extracted cancer-associated fibroblasts from 5 patients with non-small lung cancer and cultured them, stained A549 cultured alone and co-cultured with CAFs treated with CUDU907 and PDL-1. RNA sequencing was used to analyze differently expressed genes the A549 treated with CUDU907 and A549 in the co-culture system, and qPCR was used to verify the results of RNA sequencing. Then the expression of NDRG1 in cancer and paracancerous tissues was verified by immunochemical and WB experiments. A549 was transfected with siRNA to verify the effect of NDRG1 on the proliferation and migration of A549, as well as the phenotype of CAFs.

Results We found that the synergy between CUDU907 and PD-L1 is more significant in killing tumor cells, and CUDU907 can promote the expression of NDRG1 in A549, which is more obvious in the co-culture system with CAFs. Compared with paracancerous tissues, NDRG1 was more prominently distributed in tumor tissues of patients with non-small cell lung cancer, but there was no significant correlation with the degree of differentiation. Compared with the control group, A549 knocked down the NDRG1 gene had a significantly increased proliferation and migration ability.

Conclusions CUDU907 can kill tumor cells by activating NDRG1, and CAFs can also promote CUDU907 to activate NDRG1.

Ethics Approval All specimens were collected with the approval of the Institutional Review Board of Shanghai Pulmonary Hospital, and written informed consent was obtained from all patients and control participants.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.